Denali治療 DNLI 深 滬
已收盤 02-06 16:00:00 美东时间
21.08
+1.060
+5.29%
華盛通- 最 高21.31
- 今 開20.40
- 成交量 164.83万股
- 最 低 20.36
- 昨 收 20.02
- 總市值 32.92亿
- 52周最高 23.77
- 市盈率 靜 --
- 換手率 1.06%
- 52周最低 10.57
- 委 比 82.21%
- 總股本 1.56亿
- 歷史最高 93.94
- 量 比 0.86
- 振 幅 4.75%
- 歷史最低 10.57
- 每 手 1
- 風險率 2.44%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BTIG Reiterates Buy on Denali Therapeutics, Maintains $32 Price Target
BTIG analyst Thomas Shrader reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $32 price target.
02-06 18:20
Denali Therapeutics Presents Data On Enzyme TransportVehicle Programs At 2026 WORLDSymposium
Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently under FDA Priority ReviewPreliminary data from Phase 1/2 study of DNL126
01-30 05:04
Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™
Denali Therapeutics will present clinical and preclinical data on its ETV programs for Hunter syndrome, Sanfilippo syndrome type A, and Pompe disease at the 22nd Annual WORLD Symposium. Highlights include updated Phase 1/2 data for tividenofusp alfa ( Hunter syndrome), preliminary results for DNL126 (Sanfilippo type A), and the Phase 1 study design for DNL952 (Pompe disease). The FDA is reviewing tividenofusp alfa's BLA with a decision expected b...
01-29 21:00
Denali Therapeutics shares are trading higher after the company announced key 2026 milestones including the commercial launch of Tividenofusp alfa for Hunter syndrome with April 5 PDUFA date and multiple clinical readouts.
Denali Therapeutics shares are trading higher after the company announced key 2...
01-07 02:50
Denali Shares Phase 1/2 Results for Rare Disease Treatment as FDA Reviews Accelerated Approval
Denali Therapeutics Inc. (NASDAQ:DNLI) today announced the publication of results from the open-label Phase 1/2 clinical trial of its investigational, next-generation enzyme replacement therapy (ERT), tividenofusp alfa
2025-12-30 21:02
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
<p><strong>Tividenofusp Alfa Phase 1/2 Trial Results Summary:</strong> Tividenofusp alfa, an investigational enzyme replacement therapy targeting Hunter syndrome (MPS II), demonstrated significant reduction in key biomarkers such as cerebrospinal fluid (CSF) and urine heparan sulfate (HS), as well as serum neurofilament light (NfL) chain levels, indicating reduced neuronal injury. Clinical outcomes included liver volume normalization, improved he...
2025-12-30 13:00
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
2025-12-12 10:24
Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $30
Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and lowers the price target from $31 to $30.
2025-12-11 22:31
Denali Therapeutics Announces $200M Public Offering
Denali Therapeutics ( ($DNLI) ) has shared an update. On December 9, 2025, Dena...
2025-12-11 06:49
Denali Therapeutics dips after pricing $200M equity offering
Denali Therapeutics priced its public offering of 9.14M shares at $17.50 each, plus pre-funded warrants to purchase around 2.29M shares at $17.49 per pre-funded warrant. Click here to read more. More ...
2025-12-10 18:34
